Connect with us

Hi, what are you looking for?

Jewish Business News


Has a drug for Alzheimer’s finally been found? Biogen surged 21% After Positive topline results

First late-stage study positive results from a large-scale clinical trial of Biogen’s BAN2401 experimental drug and its Japanese partner, Isa.

Biogen Inc. surged after an Alzheimer’s drug known as BAN2401 phase 2b showed positive results in a large clinical trial, raising hopes for early disease’s patients.

According to Biogen and its Japanese partner Eisai Co. announcement that the highest treatment dose of BAN2401, an anti-amyloid beta protofibril antibody, began to show statistically significant clinical benefit as early as 6 months including at 12 months.

“The study is a bright spot — if a tenuous one — in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed” Bloomberg reports. “Drugmakers have persisted in part because of the size of the potential market — as much as $30 billion in the U.S. alone, according to Sanford C. Bernstein & Co. analysts.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

The success of BAN2401 will depend on the details of the data, set to be presented at a medical meeting, according to Bloomberg Intelligence analyst Sam Fazeli.”

While the ultimate outcome remains far from certain, the study is a bright spot — if a tenuous one — in the search for a treatment for Alzheimer’s, where

In December 2017, the study did not achieve its primary outcome measure which was designed to enable a potentially more rapid entry into Phase 3 development based on Bayesian analysis at 12 months of treatment.

Following the predefined study protocol, the blinded study continued with a comprehensive final analysis on treatment conducted at 18 months. Upon the final analysis at 18 months using predefined conventional statistical method, the study did demonstrate a statistically significant slowing of disease progression on the key clinical endpoint after 12 months of treatment in patients receiving the highest treatment dose (10 mg/kg twice a month) as compared to placebo. The study is ongoing with a further follow-up assessment at 21 months.

Detailed results of the study will be presented at future scientific conferences.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.